ONCOGENIC DRIVERS ARE CONSIDERED PREDICTIVE BIOMARKERS IN NSCLC

BRAF V600

IS AN ACTIONABLE TARGET IN METASTATIC NSCLC

THE FIRST AND ONLY FDA-APPROVED targeted combination therapy for patients with metastatic NSCLC with BRAF V600 mutation

TAFINLAR
Summary of Product Characteristics

MEKINIST
Summary of Product Characteristics